takhzyro solution
takeda canada inc - lanadelumab - solution - 300mg - lanadelumab 300mg - complement inhibitors
takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedemas, hereditary - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.
takhzyro
takeda israel ltd - lanadelumab - solution for injection - lanadelumab 150 mg/ml - lanadelumab - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae)in patients aged 2 years and older.
takhzyro solution
takeda canada inc - lanadelumab - solution - 300mg - lanadelumab 300mg - complement inhibitors
takhzyro
takeda new zealand limited - lanadelumab 150 mg/ml; - solution for injection - 300 mg/2ml - active: lanadelumab 150 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate dihydrate histidine polysorbate 80 sodium chloride water for injection - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angiodema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years or older.
takhzyro lanadelumab 300 mg/2 ml solution for injection pre-filled syringe
takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.
takhzyro lanadelumab 300mg/2ml solution for injection vial
takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.